NCT00139919已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with the current Diagnosis of Schizophrenia, Bipolar Type I Disorder according to DSM-IV TR criteria
- •Age 18 to 55
- •Body weight 100-250 lbs
- •Be sufficiently stable to allow discontinuation of antipsychotic medication
排除标准
- •Acutely psychotic subjects
- •Subjects that are acutely manic
- •Subjects with a psych diagnosis other than Bipolar Type I Disorder
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A phase 2 clinical study to evaluate the efficacy, safety and tolerability of TransT3-60 vs placebo (a powder administered sublingually) in participants with Non-Alcoholic SteatoHepatitis (NASH)iver- Non-Alcoholic SteatoHepatitis (NASH)Liver- Non-Alcoholic SteatoHepatitis (NASH)Inflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12621001710819Invictus Ops Pty Ltd80
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002338-21-GBAlbireo AB60
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002338-21-FRAlbireo AB60
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002338-21-BEAlbireo AB60
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002338-21-DEAlbireo AB62